CagriSema peptide combines cagrilintide and semaglutide for weight loss. See how it works, trial results, side effects, and current FDA status.
CagriSema is not a single peptide. It is an investigational once-weekly injection that combines two peptides: cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist. Novo Nordisk developed the combination for chronic weight management and type 2 diabetes, and it is not FDA-approved for any human use in the United States.
Most people searching this term want one of three things: what the drug actually is, what the trial results show, or where to buy it. The first two have clear answers. The third does not.
What Is CagriSema?
CagriSema pairs two molecules that work on appetite and blood sugar through different receptors. Cagrilintide mimics amylin, a hormone released alongside insulin that slows stomach emptying and increases feelings of fullness. Semaglutide mimics GLP-1, which boosts glucose-dependent insulin release and reduces appetite through the brain.
Because the pathways are separate, researchers expected the combination to outperform either peptide alone. The name is simply a blend of the two: "cagri" from cagrilintide and "sema" from semaglutide.
The drug is given as a once-weekly subcutaneous injection, which is one practical advantage over daily options. It is still an investigational product, not a marketed medication.
CagriSema Peptide Benefits Reported in Trials
Novo Nordisk studied the combination in the REDEFINE phase 3 program. In REDEFINE 1, adults with obesity but without diabetes lost roughly 20% of their body weight on average over 68 weeks.
REDEFINE 2 tested CagriSema in adults with type 2 diabetes and excess weight. Average weight loss there was about 16% at 68 weeks, along with meaningful improvements in blood sugar control.
A separate head-to-head study, REDEFINE 4, compared CagriSema with tirzepatide 15 mg. Tirzepatide produced greater weight loss, so CagriSema did not demonstrate superiority over the strongest competitor currently on the market.
Reported benefits in trials include:
- Large average reductions in body weight in people with and without type 2 diabetes
- Improved HbA1c among participants with diabetes
- Once-weekly dosing instead of daily injections
- Appetite suppression that appeared stronger than semaglutide alone in some comparisons
These numbers come from controlled trials with specific populations, not from consumer use. Individual results vary widely, and no peptide produces the same outcome in every person.
How CagriSema Compares With Other Weight-Loss Drugs
| Option | Mechanism | Average weight loss in trials | Dosing | Status |
|---|---|---|---|---|
| Wegovy (semaglutide 2.4 mg) | GLP-1 agonist | About 15% at 68 weeks | Weekly injection | FDA-approved |
| Zepbound (tirzepatide) | GIP + GLP-1 agonist | About 21% at 72 weeks | Weekly injection | FDA-approved |
| CagriSema | Amylin + GLP-1 agonist | About 20% at 68 weeks | Weekly injection | Investigational |
| Compounded semaglutide | GLP-1 agonist | Variable | Weekly injection | Heavily restricted by FDA |
Cross-trial comparisons are rough because each study enrolled different populations with different starting weights and health conditions. The cleanest comparison remains REDEFINE 4, where tirzepatide outperformed CagriSema directly.
CagriSema Reconstitution and the Research-Peptide Market
CagriSema is manufactured as a finished, prefilled injection pen. Patients never reconstitute it, and no published protocol exists for dissolving it from a powder.
Searches for "CagriSema reconstitution" almost always trace back to gray-market research peptide vendors. Those sellers ship lyophilized powders that buyers mix with bacteriostatic or sterile water before use. The catch is that no one can verify what is inside a vial labeled CagriSema, because the real product is a two-peptide blend that has never been sold as a research chemical.
The same due diligence applies here as it does when someone tries to work out where to buy bpc-157 peptide from an online supplier. Certificates of analysis can be fabricated, and purity claims are rarely independently audited.
If you are new to this space, it helps to understand what is bpc 157 peptide first, because the labeling, storage, and handling problems are nearly identical across the gray market. Related questions such as what is kpv peptide used for follow the same pattern: a compound gets media attention, and buyers rush in before human data exists.
Just as nobody can responsibly explain how to dose kpv peptide for a condition it was never approved to treat, no one can give you a verified CagriSema dose outside a clinical trial.
Side Effects and Safety Considerations
Because CagriSema contains semaglutide, it carries the same class warnings as other GLP-1 medications, plus the gastrointestinal effects associated with amylin analogs.
- Nausea, vomiting, diarrhea, and constipation — the most common complaints, often temporary
- Abdominal pain and injection-site reactions
- Gallbladder disease, including gallstones
- Pancreatitis (rare)
- Loss of lean muscle mass alongside fat during rapid weight loss
- Boxed warning for thyroid C-cell tumors; contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2
People with kidney disease, a history of pancreatitis, or who are pregnant or breastfeeding should talk with a healthcare professional before using any GLP-1 or amylin-based drug. Dose adjustments and monitoring are not optional with this drug class.
Legal Status and What to Watch
CagriSema is not FDA-approved for weight loss, diabetes, or any other indication in the United States. Novo Nordisk has said it intends to seek regulatory approval, and any timeline depends on ongoing regulatory review.
The FDA has repeatedly warned about counterfeit and mislabeled GLP-1 products, including online sellers advertising "research grade" semaglutide. Buying an unapproved blend labeled CagriSema means unknown dosing, unknown contamination, and no recourse if something goes wrong.
For anyone genuinely interested in this drug class, the safer path is a prescription for an approved medication, managed by a clinician who can adjust the dose and monitor side effects.
Frequently Asked Questions
Is CagriSema the same thing as semaglutide?
No. CagriSema combines semaglutide with cagrilintide, an amylin analog that works through a different receptor. Semaglutide by itself is FDA-approved as Ozempic and Wegovy, while the combination product is still investigational.
Can you buy CagriSema peptide online?
There is no legitimate retail or research supply of CagriSema. The real product is a two-drug combination made by Novo Nordisk and is not FDA-approved, so websites selling "CagriSema peptide" are shipping unverified material. The FDA has warned repeatedly about counterfeit GLP-1 products sold online.
How much weight loss does CagriSema cause?
In the REDEFINE 1 trial, adults with obesity without diabetes lost about 20% of their body weight on average over 68 weeks. REDEFINE 2, which enrolled people with type 2 diabetes, showed roughly 16% average weight loss. A head-to-head trial found that tirzepatide produced greater weight loss than CagriSema.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.